ArticleCommunications medicine2022
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology.
Article in Communications medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 168 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 1 synthesis or guideline pooled it, 247 citations in OpenAlex.
- Integration of microphysiological systems with computational and digital twin modeling for pharmaceutical development: a systematic review.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Pooled it
- Introduction to the 3RsC's cross-platform microphysiological systems evaluation for drug-induced liver injury in collaboration with FDA-CDER.Regulatory toxicology and pharmacology : RTP · 2026Article
- A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Reverse bioengineering of the liver: developmental principles for next-generation liver-on-a-chip systems.Communications biology · 2026Review
- Versatile Microfluidic System for Creating Recirculating Unidirectional Flow for On-Chip Cultures of Barrier Tissues.Bioengineering (Basel, Switzerland) · 2026Article
- Assessing drug-induced liver injury liabilities in human and animal hepatocytes under static and perfused spheroid culture conditions.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Detecting drug-induced nephrotoxicity using simultaneous label-free autofluorescence multiharmonic microscopy.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Integrating Artificial Intelligence with Emerging Pharmaceutical Technologies: Current Progress, Clinical Translation, and Future Challenges.International journal of molecular sciences · 2026Review
- Integration of biological avatars and digital twins for "ex vivo clinical trials".EBioMedicine · 2026Review
- In Vitro Three-Dimensional Human Liver Model for Drug-Induced Liver and Bile Duct Injury Prediction.Toxics · 2026Article
- Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine.Protein & cell · 2026Review
- New approach methodologies for next-generation risk assessment of nanomaterials and nano-enabled products.Nano convergence · 2026Review
- Automation of 3D liver spheroid generation and acetaminophen dose-response on the MO:BOT enhances assay robustness and precision.Scientific reports · 2026Article
- From monolayer to organoids and multi-organ microphysiological systems: advancing regenerative medicine and precision therapies.Stem cell research & therapy · 2026Review
- Advances in In Vitro Vascularization of Engineered Tissues: From Microvessel Formation to Hepatic Tissue Integration.Regenerative therapy · 2026Article
- Multimodal Multiorgan-on-a-Chip Platform for Probing Liver-Tumor Interactions and Advancing Prodrug Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Organoids, organ-on-a-chip, and microtumors: Biomimetic 3D tumor models advancing drug development and precision medicine.Acta pharmaceutica Sinica. B · 2026Review
- New Frontiers of Drug Development Through the Use of New Approach Methodologies.The AAPS journal · 2026Review
- We need less animal research, better animal research, and animal research done for the right reasons.Journal of translational medicine · 2026Article
- Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
108 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
32 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional preclinical models often miss drug toxicities, meaning the harm these drugs pose to humans is only realized in clinical trials or when they make it to market. This has caused the pharmaceutical industry to waste considerable time and resources developing drugs destined to fail. Organ-on-a-Chip technology has the potential improve success in drug development pipelines, as it can recapitulate organ-level pathophysiology and clinical responses; however, systematic and quantitative evaluations of Organ-Chips' predictive value have not yet been reported.
methods870 Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury caused by small molecules identified as benchmarks by the Innovation and Quality consortium, who has published guidelines defining criteria for qualifying preclinical models. An economic analysis was also performed to measure the value Liver-Chips could offer if they were broadly adopted in supporting toxicity-related decisions as part of preclinical development workflows.
resultsHere, we show that the Liver-Chip met the qualification guidelines across a blinded set of 27 known hepatotoxic and non-toxic drugs with a sensitivity of 87% and a specificity of 100%. We also show that this level of performance could generate over $3 billion annually for the pharmaceutical industry through increased small-molecule R&D productivity.
conclusionsThe results of this study show how incorporating predictive Organ-Chips into drug development workflows could substantially improve drug discovery and development, allowing manufacturers to bring safer, more effective medicines to market in less time and at lower costs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.